Analysts from the hosting firm talked up their takeaways on biopharma from the J.P. Morgan (JPM) Healthcare Conference and looked ahead to 2024, anticipating a generally better year than those in the recent past.
U.S. biopharma Sermonix Pharmaceuticals Inc. handed off China rights of lasofoxifene, an oral endocrine therapy in development for breast cancer, to Shanghai’s Henlius Biotech Inc., for an undisclosed up-front payment and up to $58 million in milestone fees.
U.S. biopharma Sermonix Pharmaceuticals Inc. handed off China rights of lasofoxifene, an oral endocrine therapy in development for breast cancer, to Shanghai’s Henlius Biotech Inc., for an undisclosed up-front payment and up to $58 million in milestone fees.
A company launched by Alphabet Inc.’s Deepmind in 2021, Isomorphic Labs Ltd., entered its first biopharmaceutical partnerships to discover small-molecule therapeutics with Eli Lilly and Co. and Novartis AG in deals worth $1.75 billion and $1.24 billion, respectively.
If there is one therapeutic area for which numerous biopharma companies and investors have shown increasing amounts of interest in 2023, it is obesity through follow-on glucagon-like peptide-1 receptor agonists, as well as combination and solo efforts with other potential mechanisms. Analysts have suggested the obesity market (which includes overweight individuals) could grow to more than $50 billion by 2030. At least.
Fauna Bio Inc. has signed a multi-year agreement with Eli Lilly and Co. to apply Fauna’s Convergence artificial intelligence (AI) platform to support preclinical drug discovery efforts in obesity.
Eli Lilly & Co. has patented new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of Aicardi-Goutieres syndrome, dermatomyositis, systemic lupus erythematosus and lupus nephritis.
Given what CEO Raymond Stevens called a space that’s “evolving extremely rapidly,” Structure Therapeutics Inc. chose – rather than wait for next year’s 12-week data – to unblind the eight-week obesity findings with GSBR-1290, an oral glucagon-like peptide-1 (GLP-1) agonist for which the firm also provided a phase IIa update in patients with type 2 diabetes.
Five months since Eli Lilly and Co.’s $2.4 billion buyout of Dice Therapeutics Inc. and its Delscape platform for oral small-molecule inhibitors of protein-protein interactions, Lilly rolled the dice again for novel PPI targets by partnering with Japanese biotech Prism Biolab Co. Ltd.
